NovoCure's Other Operating Expenses fell 214.61% to $58.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $238.8 million, marking a year-over-year increase of 345.48%. This contributed to the annual value of $239.1 million for FY2024, which is 540.28% up from last year.
According to the latest figures from Q3 2025, NovoCure's Other Operating Expenses is $58.5 million, which was down 214.61% from $57.1 million recorded in Q2 2025.
In the past 5 years, NovoCure's Other Operating Expenses registered a high of $67.4 million during Q4 2024, and its lowest value of $31.4 million during Q1 2021.
Over the past 5 years, NovoCure's median Other Operating Expenses value was $55.2 million (recorded in 2024), while the average stood at $49.9 million.
As far as peak fluctuations go, NovoCure's Other Operating Expenses surged by 4002.66% in 2023, and later tumbled by 320.07% in 2024.
NovoCure's Other Operating Expenses (Quarter) stood at $39.0 million in 2021, then increased by 27.31% to $49.6 million in 2022, then grew by 19.26% to $59.2 million in 2023, then grew by 13.89% to $67.4 million in 2024, then fell by 13.15% to $58.5 million in 2025.
Its Other Operating Expenses was $58.5 million in Q3 2025, compared to $57.1 million in Q2 2025 and $55.8 million in Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value